Health Professionals

Two anti-PD-1 agents are currently approved for adjuvant therapy for patients with stage II melanoma. Experts say that treatment decisions for these patients are not always clear cut and that individual factors weigh in heavily. Listen as Allison Betof Warner, MD, PhD, from Stanford University, Rodabe N. Amaria, MD, from the University of Texas MD Anderson Cancer Center, and Sapna Patel, MD, from the University of Colorado, discuss the results of the CheckMate 238 trial and how those findings inform their care decisions, as well as how they approach complex discussions with these patients.

There is a positive association between melanoma and Parkinson’s disease (PD), with the risk for melanoma ranging between 1.4- and 20-fold among individuals with PD. The risk is bidirectional, too, because there is also a 1.7- to 4.2-fold increased risk for PD in patients with melanoma. The link between PD and melanoma is not well understood, but increased expression of the PD-associated protein alpha-synuclein (?Syn) in melanoma cells may provide insight into the positive association between the two diseases.

A new study from researchers at Moffitt Cancer Center shows that blocking a chemical process called nitrosylation could make one of the most aggressive forms of melanoma more treatable.